Ocugen Approaches Critical Financial and Clinical Milestones

Biotechnology firm Ocugen stands at a pivotal juncture as it prepares to release third-quarter financial results on Wednesday, November 5. The upcoming earnings report arrives at a time when the company is advancing multiple clinical programs while simultaneously facing significant financial pressures. Investors will be watching closely to see if management can demonstrate tangible progress that justifies continued investment in its pipeline.

The company’s dwindling cash reserves present a substantial challenge. At the conclusion of the second quarter, Ocugen held just $27.3 million in liquid assets. Management did secure some financial breathing room in August through a $20 million capital raise with investor Janus Henderson. Market analysts project a third-quarter loss of approximately $0.06 per Read more...